In the subset of patients with R/R extranodal NKTCL from a single-arm phase 2 study of the SMILE regimen (dexamethasone/methotrexate/ifosfamide/L-asparaginase/etoposide), the ORR after two cycles of treatment was 77.8% (N = 18) [27]. Here, ASPG is linked to extranodal nasal NK/T cell lymphoma.